Is Ozempic Safe? 40,000 Patients, SELECT Study & Honest Answer

When you first hear about weight loss injections, the first question is obvious. Is it safe? Won't it harm the heart, pancreas, thyroid? And honestly, these questions are absolutely logical.

But here's what's interesting. Ozempic wasn't studied on hundreds of people. Not even thousands. Over 40,000 patients went through semaglutide clinical trials. The results? They changed medicine's view on this class of products.

Quick answer for those in a hurry

Ozempic has been on the market since 2017. The FDA first approved it for type 2 diabetes, and in 2021 Wegovy (the same semaglutide in a higher dose) received approval for weight management.

But the real breakthrough came in 2023. The SELECT study with 17,604 patients proved what no one expected. Semaglutide isn't just safe for the heart. It actively protects it.

In 2024, the FDA expanded Wegovy indications based on this data. The product is now officially approved for cardiovascular risk reduction. This is a unique position among all weight management products.

Average weight loss in SELECT was 9.4% versus 0.9% on placebo. But researchers noted an interesting detail. Cardiovascular benefits were disproportionately greater than could be explained by weight loss alone. Something else is happening at the molecular level.

You can learn more about Ozempic and its mechanism of action on our page.

STEP and SUSTAIN: safety database of 40,000+ patients

SELECT isn't the only study. The STEP (weight loss) and SUSTAIN (diabetes) programs covered even more people.

STEP 5, for example, lasted 2 years and showed a stable safety profile. Gastrointestinal disorders (nausea, diarrhea, vomiting, constipation) were the most common side effects. They occurred in 82.2% of semaglutide participants versus 53.9% on placebo.

But here's the key. Most of these reactions were mild to moderate and temporary. Only 3.9% of participants discontinued due to gastrointestinal side effects.

If you're interested in a detailed list of Ozempic side effects, we've prepared a separate article.

Pancreatitis: what the data says, not the fears

Everyone who googled Ozempic came across the word 'pancreatitis'. And it's indeed an important topic. But let's look at the numbers.

In clinical trials, the risk of pancreatitis on semaglutide was approximately 0.2-0.3%. On placebo, this figure was around 0.3%. The difference? Statistically insignificant.

This doesn't mean the risk is zero. GLP-1 agonists generally have some association with pancreatitis, and the FDA continues monitoring. If you have a history of pancreatitis, specialists will definitely consider this before starting the program.

But panic headlines on the internet? They don't match real clinical data. The risk exists, but it's minimal and manageable under supervision.

Thyroid gland: explaining the boxed warning

When you open Ozempic instructions, the first thing you see is a black box. Boxed warning. Warning about medullary thyroid carcinoma.

Sounds scary. But here's the context.

This warning is based on rodent studies. In rats that received GLP-1 agonists in high doses for extended periods, thyroid tumors were found.

But humans aren't rats. And here's what we know after 7+ years of semaglutide use in humans: no confirmed link between GLP-1 agonists and thyroid cancer in humans has been found.

Boxed warning is not confirmation of danger. It's a precautionary measure based on preclinical data. The FDA requires it for the entire class of GLP-1 agonists, including semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro).

If you have no contraindications, the risk remains theoretical, not practical.

'Ozempic Face': why this is NOT a product side effect

You've probably seen those photos. Faces that look tired, with volume loss, wrinkles. 'Ozempic Face' became a viral term.

But let's be honest. This isn't a specific effect of Ozempic. It's an effect of any rapid weight loss.

When a person loses significant weight, facial fat tissue also decreases. Skin that has stretched doesn't have time to contract. The result? Visual changes that may look like 'aging'.

This applies to diets, bariatric surgery, any weight loss method. Ozempic just became the most popular, so it got its own name for this phenomenon.

We wrote more about Ozempic Face and how to prevent it in a separate article.

Who shouldn't take Ozempic: honest list

No product suits everyone. And we at DOZA always check contraindications before recommending a program.

Absolute contraindications:

• Medullary thyroid carcinoma (personal or family history)
• MEN2 syndrome
• Pregnancy and breastfeeding
• Known allergy to semaglutide

Caution needed with:

• History of pancreatitis
• Diabetic retinopathy
• Severe kidney disease
• Gallbladder disease

That's why specialist consultation isn't a formality. We analyze your history to ensure the program suits you specifically.

If after reviewing SELECT safety data you're considering an even stronger option with a similar safety profile — Buy Mounjaro in Ukraine (tirzepatide, GLP-1 + GIP) shows in SURMOUNT-1 an average weight loss of -22.5% versus -15% on semaglutide. UK-original KwikPen Eli Lilly, all doses, thermal box, 1–2 days across Ukraine.

Where to order DOZA products

DOZA supplies all products mentioned in the article with official cold chain and 24/7 specialist support. Choose what you need:

• Buy Ozempic in Ukraine — original semaglutide from Novo Nordisk with thermal delivery. Current Ozempic prices 2026 — from 1,600 ₴ for the starting dose.